Article
Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Apr 2010
Gallagher David J, Gaudet Mia M, Pal Prodipto, Kirchhoff Tomas, Balistreri Lisa, Vora Kinjal, Bhatia Jasmine, Stadler Zsofia, Fine Samson W, Reuter Victor, Zelefsky Michael, Morris Michael J, Scher Howard I, Klein Robert J, Norton Larry, Eastham James A, Scardino Peter T, Robson Mark E, Offit Kenneth
Abstract excerpt
PURPOSE: Increased prostate cancer risk has been reported for BRCA mutation carriers, but BRCA-associated clinicopathologic features have not been clearly defined. EXPERIMENTAL DESIGN: We determined BRCA mutation prevalence in 832 Ashkenazi Jewish men diagnosed with localized prostate cancer between 1988 and 2007 and 454 Ashkenazi Jewish controls and compared clinical outcome measures among 26 BRCA mutation...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.